Hemoglobin News and Research

RSS

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.

15 Jun 2012

Third Rock Ventures announces formation of Global Blood Therapeutics

Third Rock Ventures, LLC today announced the formation of Global Blood Therapeutics, Inc. and its $40.7 million Series A financing of the company.

15 Jun 2012

Oxidative stress linked to NSS severity in schizophrenia

The severity of neurologic soft signs negatively correlates with antioxidant superoxide dismutase activity in patients with schizophrenia, research shows.

14 Jun 2012

Rising blood sugar points to developing stroke risk

People with prediabetes have a somewhat increased risk for stroke, say the authors of a meta-analysis.

13 Jun 2012

Short-term intensive weight management program effective alternative to bariatric surgery

A study by a team of clinicians and researchers at the Joslin Diabetes Center in Boston has shown for the first time that patients with diabetes who enrolled in a short-term intensive weight management program were able to lose weight and keep it off on their own for four years.

13 Jun 2012

Clinical utility of Metabolon's Quantose IR test to be showcased at ADA meeting

Metabolon, Inc. announces that the clinical utility of the Company's lead diagnostic product Quantose IR will be featured in five poster presentations at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) being held June 8-12 in Philadelphia.

12 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Researchers identify new mitochondrial protein complex linked with type 2 diabetes

Researchers at Metabolic Solutions Development Company, LLC (MSDC) have identified a mitochondrial protein complex through which anti-diabetic drugs exert their insulin sensitizing effects when used to treat patients diagnosed with type 2 diabetes.

11 Jun 2012

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.

11 Jun 2012

Incyte, Lilly announce 12-week results from baricitinib Phase IIb study on RA

Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis.

11 Jun 2012

Researchers shed light on key biological events that may lead to new disease treatments

In exploring how proteins interact with crucial DNA sequences to regulate gene activity, researchers have shed light on key biological events that may eventually be manipulated to provide new disease treatments.

8 Jun 2012

Study assesses impact of postoperative nHb and transfusion in patients with PAD

Vascular surgeons from Baylor College of Medicine and the Michael E. DeBakey Veterans' Administration Medical Center in Houston, TX, have released a study about the impact of transfusion and postoperative nadir postoperative hemoglobin (nHb) on short- and long-term outcomes after interventions for peripheral arterial disease.

8 Jun 2012

Millions of pre-diabetic Americans may be at increased risk of future stroke

Millions of pre-diabetic Americans may be at increased risk of future stroke, say researchers at the University of California, San Diego School of Medicine in a new meta-analysis of epidemiological studies, but the precise degree of that threat is confounded by differing medical definitions and factors that remain unknown or unmeasured.

8 Jun 2012

GLP-1 receptor agonist boosts glycemic control in Asian patients

Adding once-daily lixisenatide to basal insulin treatment is effective at improving glycemic control in Asian patients with Type 2 diabetes, show study findings.

6 Jun 2012

MBC receives $50,000 FABC grant to further research into blood donor safety

Memorial Blood Centers (MBC), a national leader in transfusion medicine, today announced the receipt of a $50,000 grant from The Foundation for America's Blood Centers (FABC) that will further research into blood donor safety.

6 Jun 2012

Exelixis reports positive interim data from cabozantinib phase 2 trial on HCC

Exelixis, Inc. today reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.

4 Jun 2012

Glucocorticoid steroids in intelligent medicine specifically hits relevant cells

Scientists at Aarhus University, Denmark in collaboration with the biotech company Cytoguide now publish a key to use glucocorticoid steroids in a kind of intelligent medicine that specifically hits the relevant cells. Data are based on rodent studies but if this principle is translated to humans it may greatly improve todays hazardous treatment with this type of potent steroids.

1 Jun 2012

Intensive wellness program addresses multiple aspects of diabetes care

An integrated wellness team approach to diabetes care is helping patients lower their prescription costs and improve their condition, according to research presented today at the American Association of Clinical Endocrinologists' (AACE) 21st Annual Scientific & Clinical Congress in Philadelphia.

28 May 2012

ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen

Baxter International Inc. today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal disease (ESRD) patients with diabetes, including blood glucose (sugar) control and selected lipids.

From Baxter International Inc. 28 May 2012

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

25 May 2012